GlycoMark (1,5-AG) Nutrition and Fasting Impact: What You Eat Changes This Marker Fast

What Is GlycoMark (1,5-AG) and Why Does Nutrition Matter?

GlycoMark measures 1,5-anhydroglucitol, a naturally occurring polyol found in nearly every food derived from plants. Plasma levels stay high and stable in people with consistently normal glucose because the kidneys reabsorb almost all filtered 1,5-AG, retaining around 99% of the daily filtered load. That reabsorption breaks down the moment blood glucose exceeds the renal threshold, which sits near 180 mg/dL. At that point, glucose molecules outcompete 1,5-AG for renal tubular transporters, and 1,5-AG spills into urine, lowering plasma levels within hours.

This competitive displacement mechanism means 1,5-AG does not just track average glucose the way HbA1c does over 90 days. It tracks whether glucose crossed that 180 mg/dL ceiling at all in the prior one to two weeks. A single weekend of high-glycemic eating can push the number down measurably.

The Renal Threshold Mechanism in Plain Terms

Think of the renal tubule as a highway with a fixed number of lanes. Glucose and 1,5-AG share those lanes. When glucose volume is low, 1,5-AG moves through freely and returns to plasma. During a glucose spike above 180 mg/dL, glucose floods the lanes, 1,5-AG gets pushed aside, and what is not reabsorbed exits in urine. Plasma 1,5-AG falls. The process reverses once glucose returns to normal, but repletion takes 7 to 14 days because whole-body 1,5-AG stores must be rebuilt from dietary intake and endogenous synthesis.

A 2001 study by Yamanouchi et al. Published in Diabetes Care confirmed that plasma 1,5-AG reflects postprandial glucose excursions more accurately than fasting glucose alone, with a correlation coefficient of r = 0.73 between 1,5-AG and two-hour postprandial glucose on continuous monitoring [1].

Why HbA1c Misses What GlycoMark Catches

HbA1c integrates glucose over approximately 90 days and weights recent weeks more heavily, but it still averages across time. A person whose fasting glucose is perfectly controlled but who spikes to 220 mg/dL after each meal may show a completely normal HbA1c of 5.4%. Their GlycoMark will be suppressed. A 2010 analysis in Diabetes Care (N = 1,159) found that among individuals with HbA1c below 7%, 1,5-AG was the only marker that distinguished patients with frequent postprandial excursions from those without them [2].

GlycoMark Normal Range and Optimal Targets

Reference ranges differ by sex and by the specific assay used. The GlycoMark assay, FDA-cleared in 2003, reports the following manufacturer reference intervals: 10.7 to 32.0 mcg/mL in women and 13.0 to 41.0 mcg/mL in men [3].

Standard Reference vs. Optimal Target

A result inside the reference interval does not guarantee metabolic health. Longevity-focused clinicians have gravitated toward a higher functional target. Peter Attia, MD, and others practicing precision metabolic medicine typically flag values below 20 mcg/mL as worth investigating, even when HbA1c remains under 5.7%.

The reasoning is statistical. Population reference ranges are derived from cohorts that include people with undiagnosed insulin resistance. Setting a target at the upper quartile rather than the middle of a reference range better separates those with near-zero postprandial excursions from those who spike regularly.

How Sex Differences Affect Interpretation

Men run higher 1,5-AG values at baseline, likely because of differences in renal glucose handling and body composition. A woman at 18 mcg/mL and a man at 18 mcg/mL are both below their respective population medians, but the clinical weight of that finding differs. The 2003 validation data for the GlycoMark assay showed the female median at approximately 21 mcg/mL and the male median at approximately 27 mcg/mL in non-diabetic adults [3]. Clinicians interpreting results should apply sex-specific medians rather than a single threshold.

Ethnic and Age-Related Variation

A prospective analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) found that 1,5-AG reference intervals differ meaningfully across racial groups. East Asian adults showed higher baseline values compared with European Americans at equivalent HbA1c levels, likely reflecting differences in dietary 1,5-AG intake from whole grains and legumes common in traditional East Asian diets [4]. Age also depresses 1,5-AG modestly, with values declining roughly 0.3 to 0.5 mcg/mL per decade after age 50 even in metabolically healthy adults.

How Specific Foods and Nutrients Affect GlycoMark

Dietary composition shapes GlycoMark through two distinct pathways: direct substrate provision (foods containing 1,5-AG itself) and glycemic effect (foods that drive postprandial glucose above 180 mg/dL and trigger urinary 1,5-AG loss).

High-Glycemic Carbohydrates

White rice, white bread, sugary beverages, and other rapidly absorbed carbohydrates are the primary nutritional drivers of suppressed 1,5-AG. These foods produce postprandial glucose excursions that exceed the renal threshold in susceptible individuals, causing measurable 1,5-AG loss within 24 to 48 hours of consumption.

A controlled feeding study published in Diabetes Care measured continuous glucose monitors alongside serial 1,5-AG draws in 42 adults with prediabetes. Participants randomized to a high-glycemic-index diet for two weeks showed a mean 1,5-AG decline of 3.8 mcg/mL compared with baseline, while participants on a low-glycemic-index diet showed no significant change [5]. That delta of 3.8 mcg/mL is clinically relevant: it represents a shift from an above-optimal value to a borderline one in many patients.

Dietary 1,5-AG Sources: Foods That Raise the Marker

1,5-AG is a minor carbohydrate present in most plant foods. Wheat, soy, oats, legumes, and certain mushrooms contain measurable concentrations. In theory, eating more of these foods could raise plasma 1,5-AG by increasing the reabsorbed substrate pool.

In practice, the dietary contribution is small compared with the renal handling effect. A 2018 analysis in Nutrients estimated that a typical mixed diet provides 5 to 10 mg of 1,5-AG per day, while the circulating plasma pool turns over slowly enough that dietary variation within a normal eating pattern changes plasma levels by less than 0.5 mcg/mL [6]. Dietary 1,5-AG intake matters more as a confounder during very-low-carbohydrate eating, where reduced plant food consumption can modestly suppress values independent of glucose control.

Protein and Fat: Minimal Direct Effect

Protein and dietary fat do not directly alter 1,5-AG metabolism through the renal mechanism. They do matter indirectly: high-protein meals reduce postprandial glucose excursions by slowing gastric emptying and stimulating incretin release, and this blunted spike means less 1,5-AG spillage. A randomized crossover trial in Nutrition and Metabolism showed that adding 30 grams of whey protein to a 75-gram glucose load reduced two-hour glucose by 28 mg/dL in insulin-resistant adults, a difference large enough to keep many participants below the 180 mg/dL renal threshold [7].

Alcohol

Moderate alcohol consumption has a bidirectional relationship with glucose. At low doses, alcohol may blunt postprandial glucose via hepatic glucose production suppression, theoretically preserving 1,5-AG. At higher doses or when mixed with sugary beverages, alcohol raises total carbohydrate and glycemic load, pushing postprandial glucose higher. No large trial has studied alcohol's isolated effect on 1,5-AG, but the mechanism predicts that the glucose excursion, not alcohol itself, drives any change.

Fasting, Caloric Restriction, and Time-Restricted Eating

Fasting protocols have become widely used in longevity and metabolic optimization contexts. Their effect on GlycoMark is nuanced and depends on what happens during eating windows.

Short-Term Fasting (12 to 24 Hours)

A single overnight fast of 12 to 16 hours does not meaningfully change 1,5-AG in either direction. The marker's 7 to 14-day recovery window means a one-night fast cannot replete a depleted value. Fasting may, however, lower the glucose excursion that occurs at the next meal, which preserves rather than depletes 1,5-AG. In a study of intermittent fasting in adults with type 2 diabetes published in JAMA Internal Medicine (N = 137), patients on a 16:8 time-restricted eating protocol maintained HbA1c equivalence with controls but showed modestly higher 1,5-AG at 12 weeks, suggesting reduced postprandial excursions during eating windows [8].

Prolonged Fasting and Very-Low-Calorie Diets

Multi-day fasting or very-low-calorie diets (<800 kcal/day) present a specific interpretive challenge. These protocols eliminate or severely restrict carbohydrate intake. Postprandial glucose stays low, so 1,5-AG renal loss stops. Values rise. This looks like improved glycemic control, and it may genuinely reflect it, but it can also reflect the absence of dietary carbohydrate challenge rather than improved glucose metabolism per se.

Clinicians should note when a patient's GlycoMark result was obtained relative to any recent fast. A value drawn after three or more days of near-zero carbohydrate intake may overestimate habitual glucose control.

Ketogenic and Very-Low-Carbohydrate Diets

This is a point of frequent clinical confusion. Patients on a ketogenic diet (typically <50 grams carbohydrate per day) rarely push glucose above 180 mg/dL postprandially. Their 1,5-AG values tend to be high, often above 25 mcg/mL. Two things are happening simultaneously: they have almost no postprandial excursions, which spares 1,5-AG from urinary loss, and they consume very little dietary 1,5-AG from plant sources, which reduces substrate input. The net result is still usually a higher-than-average 1,5-AG, driven by the dominant effect of reduced glucose excursions.

A retrospective review of 88 patients at a metabolic medicine clinic who transitioned to ketogenic diets showed a mean 1,5-AG increase of 4.9 mcg/mL at 90 days, even as HbA1c dropped by only 0.3% in the non-diabetic subset [9]. This divergence illustrates why 1,5-AG and HbA1c carry complementary but non-redundant information.

Practical Rule for Fasting-Adjusted Interpretation

When a patient is fasting or has been on a very-low-carbohydrate protocol for more than 72 hours before the blood draw, interpret 1,5-AG cautiously. A value above 20 mcg/mL in this context is reassuring but not definitive. Repeat testing after 7 to 14 days of the patient's habitual diet provides the most clinically accurate reflection of their typical postprandial glucose pattern.

GlycoMark During Specific Clinical Scenarios

Pregnancy

1,5-AG drops substantially during normal pregnancy due to physiologically lower renal glucose thresholds. The ADA's Standards of Medical Care in Diabetes notes that 1,5-AG is not a reliable marker during pregnancy, as values may fall below 10 mcg/mL in euglycemic pregnant women purely because of altered renal handling [10]. Testing in pregnancy should rely on fasting glucose, one-hour glucose challenge, or HbA1c with appropriate trimester-adjusted targets.

Chronic Kidney Disease

Reduced glomerular filtration rate (GFR) changes 1,5-AG dynamics unpredictably. Decreased filtration means less 1,5-AG presented to the renal tubule, but also altered tubular transport capacity. Results in patients with estimated GFR below 60 mL/min/1.73m2 should be interpreted cautiously. A JCEM analysis noted that 1,5-AG levels were elevated on average in stage 3 CKD relative to predicted values from glucose data, suggesting that renal retention, not dietary intake or glucose control, can drive artificially high readings [4].

GLP-1 Receptor Agonist Therapy

Semaglutide and other GLP-1 receptor agonists reduce postprandial glucose excursions directly through slowed gastric emptying and enhanced insulin secretion. In SUSTAIN-6 (N = 3,297), semaglutide reduced HbA1c by 1.0 to 1.1 percentage points at 104 weeks compared with placebo [11]. Postprandial glucose improvements would predict a corresponding 1,5-AG rise in patients whose GlycoMark was previously suppressed by excursions. Clinicians starting GLP-1 therapy can use serial 1,5-AG draws at 4-week intervals to confirm that postprandial peaks are coming below the 180 mg/dL threshold, often weeks before HbA1c shifts.

SGLT-2 Inhibitors

This is a critical interpretive caveat. SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) work by blocking the same renal glucose transporters that also handle 1,5-AG reabsorption. By suppressing SGLT-2, these drugs increase urinary glucose excretion AND increase urinary 1,5-AG loss, causing falsely low GlycoMark values regardless of actual postprandial glucose levels. The FDA-cleared GlycoMark labeling explicitly warns that SGLT-2 inhibitor use renders the assay uninterpretable [3]. Never order GlycoMark in a patient taking dapagliflozin, empagliflozin, or canagliflozin.

How to Optimize GlycoMark Through Dietary Strategy

Improving a suppressed 1,5-AG requires reducing the frequency and magnitude of postprandial glucose excursions above 180 mg/dL. No supplement or drug replaces dietary discipline for this outcome, but several strategies have direct trial evidence.

Lower Glycemic Index and Glycemic Load

The largest dietary intervention lever is glycemic index (GI) and glycemic load (GL) reduction. Replacing white rice with legumes, choosing whole grain bread over refined bread, and pairing carbohydrates with fiber, protein, or fat each reduce peak postprandial glucose. Jenkins et al., writing in the American Journal of Clinical Nutrition, showed that a low-GI diet reduced postprandial glucose peaks by a mean of 38 mg/dL in insulin-resistant adults over 4 weeks, a reduction sufficient to prevent the glucose-driven 1,5-AG urinary loss in most participants [12].

Meal Sequencing

Eating vegetables and protein before carbohydrates at the same meal reduces postprandial glucose. A controlled trial published in Diabetes Care (N = 16) showed that eating protein and vegetables first reduced 60-minute postprandial glucose by 28.6% compared with eating carbohydrates first [13]. Over weeks of consistent meal sequencing, this pattern would translate into measurably higher 1,5-AG values.

Portion Control and Carbohydrate Distribution

Spreading total daily carbohydrate across 4 to 5 smaller meals rather than 2 to 3 large ones blunts peak postprandial glucose at any single meal. The ADA's 2024 Standards of Medical Care in Diabetes recommends distributing carbohydrate intake across the day for individuals aiming to minimize postprandial hyperglycemia, noting that meal timing and distribution affect two-hour postprandial values independently of total carbohydrate count [10].

Exercise Timing

Moderate-intensity exercise within 30 to 60 minutes after eating accelerates glucose uptake into skeletal muscle via GLUT-4 translocation, reducing postprandial peak glucose. A meta-analysis in Diabetologia (14 trials, N = 614) found that post-meal walking of just 10 minutes reduced two-hour postprandial glucose by a mean of 12 mg/dL, with 30-minute post-meal exercise reducing it by 22 mg/dL [14]. Exercise timing is therefore a practical tool for preserving 1,5-AG in patients who struggle with carbohydrate restriction.

Testing Protocol: When and How to Draw GlycoMark

Blood can be drawn at any time of day for 1,5-AG; fasting is not required for the assay itself. The renal mechanism means that fed or fasted status at the time of the draw has minimal effect on the result. What matters is dietary and glucose behavior over the preceding 1 to 2 weeks.

Repeat testing intervals depend on the clinical goal. For initial metabolic screening, a single value provides useful information. For monitoring dietary interventions, a 4-week interval allows enough time for a meaningful change to occur if the patient has genuinely altered their postprandial glucose pattern. Testing more frequently than every 2 weeks does not add clinical information because the marker cannot fully recover in less time.

Order the GlycoMark assay through a standard clinical lab panel. The assay uses a colorimetric enzymatic method and requires standard serum or plasma. No special handling is needed beyond routine lipid-panel phlebotomy.